What happened with Orthocell (ASX:OCC) in the United States?

Orthocell successfully completed its first surgical case using the Remplir nerve repair device within the U.S. Department of Defence (DoD) and Veterans Affairs (VA) hospital network.

Why is the U.S. DoD and VA network important for Orthocell (ASX:OCC)?

The DoD and VA network represents a significant scale for adoption, consisting of 51 military hospitals and 170 VA medical centres across the United States.

How quickly did Orthocell (ASX:OCC) move from approval to clinical use?

Orthocell transitioned from receiving procurement approval to performing its first live surgical case in under 48 hours. This rapid turnaround is a key performance indicator (KPI) demonstrating strong surgeon engagement and an effective logistics framework.

What is the current share price and market sentiment for Orthocell (ASX:OCC)?

At the time of this milestone announcement, Orthocell’s share price was $1.04. The successful first surgery acts as a "proof of concept" for the company's U.S. expansion, likely boosting investor confidence in management’s ability to execute.

How does Orthocell (ASX:OCC) manage its distribution in the U.S. market?

Orthocell utilises an extensive U.S. distributor footprint that currently spans 17 states to support the rollout of Remplir.

What are the main bull and bear points for Orthocell (ASX:OCC) after this news?

The bull case is that Orthocell has cracked a major, closed healthcare system (the DoD/VA) which could lead to rapid, recurring revenue and a clear valuation re-rating. The bear case/risk is that one successful surgery does not guarantee wide-scale adoption; investors must watch for potential bottlenecks in the 17-state distributor rollout.

Orthocell completes first US military surgical case

Written by Brie CarterPublished Apr. 17 2026Last Updated Apr. 17 2026

Orthocell (ASX:OCC) has reached a pivotal milestone in its international expansion, completing the first surgical case using its Remplir nerve repair device within the United States Department of Defence and Veterans Affairs hospital network.

The procedure, conducted at a military base hospital in Ohio, marks the rapid clinical adoption of the technology following the company’s recent procurement approval announced just two days prior.

By transitioning from regulatory approval to real-world clinical use in under 48 hours, the company has demonstrated high levels of surgeon engagement and a robust logistics framework.

The DoD and VA network provides a massive scale for adoption, encompassing 51 military hospitals and 170 VA medical centres nationwide.

The integrated system offers Orthocell a streamlined pathway to reach thousands of veterans and active-duty service members requiring advanced regenerative nerve treatments.

The swift implementation is supported by Orthocell’s extensive US distributor footprint, which currently spans 17 states.

The partners are providing essential in-theatre case support and efficient onboarding to ensure seamless integration into American surgical suites.

At the time of reporting, Orthocell's share price was $1.04.